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A topic dermatitis (AD) is a chronic pruritic inflammatory skin disease which is considered a 
multifactorial disease caused by both genetic and envi-
ronmental factors [1].  The pathophysiology of AD is 
roughly divided into two elements: barrier dysfunction 
in the epidermal keratinocyte layer of the skin surface,  
and systemic inflammatory reaction by various cyto-
kines/chemokines,  mainly Th2 cytokines [1].  In rela-
tion to the barrier dysfunction,  Palmer et al.  reported 
that the patients from Ireland with AD showed a high 
rate of genetic defects in filaggrin,  an epidermal barrier 
component [2].  However,  there are quite a few AD 
patients who do not carry any filaggrin gene mutations,  
and some individuals with filaggrin gene mutations do 
not develop AD [3].  Therefore,  other epidermal barrier 
factors are also likely to be associated with the patho-
genesis of AD.  There are many reports about the influ-
ence of interleukin (IL)-4 and IL-13,  which are Th2 
cytokines,  on immune cells such as T cells [4].  The 
effects of these cytokines on the epidermal barrier 
mechanism have also been described [4 , 5].
A protease with the ability to release bradykinin 
from kininogen was reported in 1930,  and it was 
named “kallikrein”,  which is derived from the Greek 
word for pancreas,  “kallikreas” [6].  The protease is now 
known as tissue kallikrein 1 (KLK1).  Plasma kallikrein 
(KLKB1) was later also discovered as another kallikrein 
that is produced mainly in the liver and circulates in the 
blood [7].  Currently,  15 types of tissue kallikreins have 
been reported,  and the 14 kallikreins other than KLK1 
are called kallikrein-related peptidases (KLK2-KLK15) 
[8].  KLK1 to KLK15 form gene clusters in the long arm 
of chromosome 19 (KLKB1 is located on chromosome 
4q34-35) [8].  KLK1 to KLK15 are transcribed to mRNA 
with five coding exons.  KLKs are produced as pre-pro-
proteins,  with N-terminal signal peptides [8].  The sig-
nal peptides are removed during secretion into the 
extracellular space,  and the propeptides are removed 
extracellularly by autocatalysis or by other KLKs or 
endopeptidases [8].
Epidermal keratinocyte-derived serine proteases 
affect the barrier formation of the epidermal stratum 
corneum.  Especially,  KLK5 (a trypsin-like serine pro-
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tease) and KLK7 (a chymotrypsin-like serine protease) 
are well known to be highly expressed in skin epidermal 
keratinocytes [9].  These KLKs are thought to promote 
the desquamation of the epidermal stratum corneum in 
normal skin by cleaving adhesion molecules such as 
desmoglein 1 (DSG1),  desmocollin 1 (DSC1),  and cor-
neodesmosin (CDSN) (Fig. 1) [9].  KLKs also activate 
IL-1β in the skin [10-12].  The elevation of pH enhances 
the serine protease activities,  and the stratum corneum 
pH is increased in AD lesions [1 , 13 , 14].
On the other hand,  in a mouse model of abnormal 
KLK activation (the mice are deficient in the KLK 
inhibitory factor lympho-epithelial Kazal-type-related 
inhibitor [LEKTI]),  a decrease in stratum corneum 
barrier function and skin eczematous inflammation are 
induced,  accompanied by the accelerated decomposi-
tion of filaggrin [15].  Loss-of-function mutations of 
SPINK5,  which encodes LEKTI,  are found in patients 
with human Netherton syndrome [16],  and it is inter-
esting that these patients develop AD-like symptoms 
and hyper-IgEemia.  p.K420E,  a single-nucleotide poly-
morphism (SNP) of SPIINK5,  was reported to be asso-
ciated with the pathogenesis of AD [17-23],  but not in 
all populations [24-29].  Fortugno et al.  showed that this 
variant has altered serine protease inhibitor function 
that results in protease deregulation [30].  It was also 
reported that KLKs are excessively expressed in AD 
lesions [31],  and it was suggested that the abnormal 
action of KLKs is involved in skin barrier dysfunction 
in AD.  In other words,  overexpressed KLKs disrupt the 
normal barrier function,  and due to that breakdown,  
external substances that can become antigens of AD 
easily invade the epidermis,  resulting in dermatitis,  
coupled with the induction of Th2 cytokines (Fig. 2).
This article reviews the association between KLKs 
and AD.  In the skin,  KLK5 , 6 , 7 , 8 , 10 , 11 , 13,  and 14 
are expressed at the protein level [32].  The article,  
therefore,  focuses on these eight KLKs associated with 
AD.
KLK5 and AD. KLK5 is a major trypsin-like ser-
ine protease in the epidermis,  and it was first reported 
and cloned as “stratum corneum tryptic enzyme 
(SCTE)” in 1999 [33].  KLK5 is capable of cleaving 
DSG1,  DSC1,  and CDSN,  leading to desquamation of 
the corneal layers (Fig. 1) [9].  KLK5 is indirectly 
involved in the processing of (pro) filaggrin by activat-
ing elastase-2,  which is a serine protease expressed in 
the epidermal layer [34].  It was recently pointed out 
that KLK5 is localized not only in lamellar granules but 
also in keratohyalin granules,  and KLK5 may be 
directly involved in the processing of profilaggrin [35].  
KLK5 also has the potential to activate the human 
cathelicidin antimicrobial peptide LL-37 [36].  KLK5 
self-activates,  and is also activated by KLK14 (Fig. 3) 
[37].
Both KLK5 expression and trypsin-like serine prote-
ase activity are upregulated in AD lesions,  and the latter 
effect is thought to decrease epidermal barrier function 
[31 , 38].  Transcription factor specificity protein 1 (Sp1) 
is significantly decreased in AD lesions,  and Sp1 silenc-
ing upregulates KLK5 expression in epidermal kerati-
nocytes,  suggesting that Sp1 expression deficiency leads 
to abnormally increased KLK5 in AD [39].  IL-4 has 
been reported to suppress Sp1 mRNA expression in 
2 Morizane Acta Med.  Okayama　Vol.  73,  No.  1
Fig. 1 The roles of KLKs in normal 
skin.  KLK5 cleaves DSG1,  DSC1,  and 
CDSN,  and KLK7 is capable of cleav-
ing the latter two.  These cleavages lead 
to the desquamation of the corneal lay-
ers in normal skin.  LEKTI tightly regu-
lates the activities of KLKs.
cultured keratinocytes,  but it did not show any direct 
effect on KLK5 expression in the cells [5 , 40].  Further 
investigation is required to clarify the exact mechanism 
of the increase of KLK5 in AD lesions.
In addition,  KLK5 induces the expression of thymic 
stromal lymphopoietin (TSLP) via protease-activated 
receptor-2 (PAR2),  which creates a Th2-rich environ-
ment [41].  The elevation of the skin pH also directly 
modulates KLK5 activity against PAR2 [14].  However,  
Zhu et al.  reported that persistent KLK5 activation 
induces AD-like skin architecture independent of PAR2 
activity [42].
Transgenic mice overexpressing human KLK5 dis-
play cutaneous and systemic hallmarks of severe 
inflammation and allergy with pruritus [43].  
Furthermore,  KLK5 is an endogenous pruritogen in a 
murine model of AD [44].
KLK6 and AD. KLK6 is a trypsin-like serine pro-
tease and its expression is detectable in the epidermis at 
the mRNA and protein levels [32 , 45].  KLK6 is acti-
vated by KLK5 (Fig. 3) [46].  Similar to KLK5,  KLK6 is 
capable of activating PAR2 [47].  The expression of 
KLK6 is increased in AD lesions [31].  Sp1 silencing 
also upregulates KLK6 expression in epidermal kerati-
nocytes [39].  Staphylococcus aureus induces KLK6 
expression and enhances the KLK6-dependent degrada-
tion of DSG1 and filaggrin,  which might be involved in 
the pathogenesis of AD [48].
KLK7 and AD. In the KLK family,  KLK7 is the 
sole chymotrypsin-like serine protease expressed in the 
epidermis,  and it was first reported as “stratum cor-
neum chymotryptic enzyme (SCCE)” in 1991 and 
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Fig. 2 Epidermal barrier dysfunction in 
AD.  Overexpressed KLKs disrupt the 
normal barrier function,  and due to this 
breakdown,  external substances that 
can become antigens of AD easily 
invade the epidermis,  resulting in der-
matitis.
Fig. 3 KLK activation cascade.  The 
activation cascade of eight KLKs 
expressed in the skin is shown.
cloned in 1994 [49 , 50].  KLK7 is capable of cleaving 
DSC1 and CDSN,  leading to desquamation of the cor-
neal layers (Fig. 1) [9].  The elevation of the pH in stra-
tum corneum that is observed in AD lesions enhances 
KLK7 activity [1 , 13].  KLK7 is activated by KLK5 
(Fig. 3) [37].
Both the expression of KLK7 and the activity of chy-
motrypsin-like serine protease are upregulated in AD 
lesions,  and the latter increase is thought to decrease 
epidermal barrier function,  as with increased KLK5 
activity [31 , 38].  However,  there has been a report 
describing that KLK7 expression was upregulated in 
tape-stripped corneocytes from AD lesions,  but the 
activity of chymotrypsin-like activity serine protease 
was not elevated [51].  Sp1 silencing also upregulates 
KLK7 expression in epidermal keratinocytes [39].  The 
Th2 cytokines IL-4 and IL-13 increase KLK7 expression 
and the protease activity in AD lesions [5].  The KLK7 
protein level in the sera of patients with AD signifi-
cantly correlates with the patient’s IL-4 levels [5].  KLK7 
also has the potential to degrade the human cathelicidin 
antimicrobial peptide LL-37 [36],  and a decrease in 
LL-37 levels has been documented in AD skin [52],  
which might account for the susceptibility of AD 
patients to skin infection.  Transgenic mice overex-
pressing human KLK7 develop chronic itchy dermatitis 
resembling AD [53].
A 3’-UTR (untranslated region) AACC insertion in 
the KLK7 gene has been reported to be significantly and 
frequently observed in AD patients,  and to cause 
increased mRNA expression without altering the gene’s 
stability [54 , 55].  However,  this variant was not signifi-
cantly associated with AD in a French cohort study [18].
KLK8 and AD. KLK8,  also known as neuropsin,  
has trypsin-like serine protease activity.  KLK8 expres-
sion is detectable in the epidermis at the mRNA and 
protein levels [32 , 45].  KLK8 is involved in the abnor-
mal proliferation or differentiation of epidermal kerati-
nocytes [56 , 57].  This protease also has the potential to 
cleave LL-37 into shorter peptides [57].  KLK8 is acti-
vated by KLK5 (Fig. 3) [57].  KLK8 is the most abundant 
trypsin-like serine protease of the KLK family in AD 
lesions [31].  Sp1 silencing also upregulates KLK8 
expression in epidermal keratinocytes [39].
KLK10 and AD. KLK10 is a trypsin-like serine 
protease and its expression is detectable in the epider-
mis at the mRNA and protein levels [32 , 45].  Although 
KLK10 activation in epidermal keratinocytes has not 
been well studied,  KLK10 expression was shown to be 
increased in AD lesions [31].  Sp1 silencing also upreg-
ulates KLK10 expression in epidermal keratinocytes 
[39].  The physiological role of KLK10 in the skin and 
the pathogenetic role of KLK10 in AD are not suffi-
ciently understood.
KLK11 and AD. KLK11 is a trypsin-like serine 
protease and its expression is detectable in the epider-
mis at the mRNA and protein levels [32 , 45].  KLK11 is 
activated by KLK8 (Fig. 3) [57],  and KLK11 expression 
is increased in AD lesions [31].  The physiological role 
of KLK11 in the skin and the pathogenetic role of KLK11 
in AD are not sufficiently understood.
KLK13 and AD. KLK13 is a trypsin-like serine 
protease and its expression is detectable in the epider-
mis at the mRNA and protein levels [32 , 45].  KLK13 
activation in epidermal keratinocytes has not been well 
studied.  The expression of KLK13 is increased in AD 
lesions [31].  Staphylococcus aureus induces KLK13 
expression and enhances the KLK13-dependent degra-
dation of DSG1 and filaggrin,  which might be involved 
in the pathogenesis of AD [48].
KLK14 and AD. KLK14 is a trypsin-like serine 
protease and its expression is detectable in the epider-
mis at the mRNA and protein levels [32 , 45].  Similar to 
KLK5,  KLK14 is capable of activating PAR2 [47].  This 
protease also has the potential to cleave LL-37 into 
shorter peptides [57].  KLK14 is activated by KLK5 
(Fig. 3) [37].  The expression of KLK14 is increased in 
AD lesions [31].  Staphylococcus aureus induces KLK14 
expression and enhances the KLK14-dependent degra-
dation of DSG1 and filaggrin,  which might be involved 
in the pathogenesis of AD [48].
Conclusion
This article has reviewed the roles of KLKs in AD.  
Many KLKs are upregulated in AD lesions and might 
play a role in the disease pathogenesis by decreasing 
epidermal barrier functions.  Further research is neces-
sary to elucidate the role of KLKs in AD.  The knowl-
edge of the role could contribute to the design of new 
therapeutic and prophylactic drugs for AD.
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